All News
Filter News
Found 500,980 articles
-
Acute Pain - 2018 Pipeline Highlights - ResearchAndMarkets.com
4/19/2018
The "Acute Pain Pipeline Highlights - 2018" report has been added to ResearchAndMarkets.com's offering.
-
BD Unveils Suite of Diagnostic Informatics and Automation Innovations
4/19/2018
BD Synapsys™ Microbiology Informatics Solution Among New Offerings Shown at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
-
Acute Myeloid Leukemia Pipeline Highlights 2018 - ResearchAndMarkets.com
4/19/2018
The "Acute Myeloid Leukemia Pipeline Highlights - 2018" report has been added to ResearchAndMarkets.com's offering.
-
Immunomic CEO to Speak at 2018 BioHealth Capital Region Forum
4/19/2018
Panel Will Discuss Strengths in BioHealth Immunotherapies
-
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
-
Sangamo Therapeutics recently filed a notice with the U.S. Securities and Exchange Commission (SEC) describing a data security breach. The incident underlines what appears to be a trend of cyber thieves attacking the biopharma industry.
-
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
-
Abbott today announced financial results for the first quarter ending March 31, 2018 and is off to a strong start to the year.
-
It seems inevitable that as marijuana becomes more broadly legal in the U.S., that the biopharma industry and larger corporations will take an interest.
-
Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
-
Public health officials and scientists have had concerns about how long Ebola vaccines’ protection lasts. A new study shows that one of those vaccines confers at least two years of protection.
-
During a meeting with U.S. Food and Drug Administration Commissioner Scott Gottlieb earlier this week, government and healthcare officials in New Jersey highlighted the need to hasten the approval of new drugs and permanently eliminate the tax on medical devices.
-
Nearly two months after Eli Lilly secured an expanded approval indication for its cancer drug Verzenio, the company unveiled final data from the MONARCH 3 trial that won the latest nod from the U.S. Food and Drug Administration for the treatment of some breast cancer patients.
-
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
-
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
-
Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference
4/18/2018
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELX:OTCQ), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts, including one Later Breaker, for its lead candidate, ELX-02 will be presented at the 41stEuropean Cystic Fibrosis Conference taking place on June 6-9, 2018 in Belgrade, Serbia.
-
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
4/18/2018
ANI expects to begin shipping product to its customers in the near future.
-
Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development
4/18/2018
Milestone achieved under the highly successful strategic alliance Evotec and Bayer entered in October 2012.
-
NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases
4/18/2018
Orphan drug designation will give the KL1333 program extra access to regulatory and scientific advice and interactions at the FDA
-
Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor Antagonist, Induces Anti-Tumor Immunity Alone and in Combination With Anti-PD-L1 in Preclinical Models
4/18/2018
New data presented at 2018 AACR Meeting